Official ESCRS | European Society of Cataract & Refractive Surgeons
Copenhagen 2016 Registration Programme Exhibitor Information Virtual Exhibition Satellite Meetings Glaucoma Day 2016 Hotel Star Alliance
title

10 - 14 Sept. 2016, Bella Center, Copenhagen, Denmark

This Meeting has been awarded 27 CME credits

 

escrs app advert yo advert

Sequential customized therapeutic keratectomy for Reis-Bücklers corneal dystrophy: long-term follow-up

Search Title by author or title

Session Details

Session Title: Surface Photoablation

Session Date/Time: Monday 12/09/2016 | 14:30-16:30

Paper Time: 16:03

Venue: Hall C1

First Author: : F.Camesasca ITALY

Co Author(s): :    P. Vinciguerra   R. Vinciguerra   S. Trazza              

Abstract Details

Purpose:

Reis-Bücklers corneal dystrophy (RBCD) is a disease progressively hindering visual acuity and causing recurrent erosions. Conventional treatment of severe cases of RBCD includes corneal transplant.We report seven-year follow up of Sequential Customized Therapeutic Keratectomy (SCTK) for the treatment of Reis-Bücklers corneal dystrophy. SCTK features a multistep customized approach with sequential intraoperative topographies. SCTK provided ongterm improvement of visual acuity, stable refraction and freedom from recurring erosions. No eye had to undergo corneal transplant and only two eyes required retreatment.

Setting:

Ophthalmology Dept., Humanitas Research Institute, Rozzano, Milan, Italy

Methods:

Fourteen eyes of 9 patients with RBCD underwent SCTK. Mean preoperative visual acuity (VA) was 0.44±0.22 with 0.14 D sph -0.81 D cyl mean correction. Mean pupillary K was 42.67 D and mean pachimetry 554.62±29.81μ.

Results:

7.44±12.33 years after surgery, mean VA was 0.78±0.24 with +0.75 D sph -1.33 D cyl mean correction. Mean pupillary K was 43.08 D and mean pachimetry 536.20±58.03μ. No patient underwent corneal transplant, and disease recurrence required retreatment in 14.2% of eyes.

Conclusions:

Seven years after SCTK, the vast majority of eyes showed improved VA and stable refraction.

Financial Disclosure:

NONE

Back to previous